Find Research Outputs

Search in all content

Filters for Research Output

Search concepts
Selected Filters

Publication Year

  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2013
  • 2012
  • 2011

Author

  • Kerry L Burnstein
2019

Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer

Zhao, N., Peacock, S. O., Lo, C. H., Heidman, L. M., Rice, M. A., Fahrenholtz, C. D., Greene, A. M., Magani, F., Copello, V. A., Martinez, M. J., Zhang, Y., Daaka, Y., Lynch, C. C. & Burnstein, K. L., Jan 1 2019, In : Science Translational Medicine. 11, 498, eaaw4636.

Research output: Contribution to journalArticle

2 Scopus citations

Reduced Arginyltransferase 1 is a driver and a potential prognostic indicator of prostate cancer metastasis

Birnbaum, M. D., Zhao, N., Moorthy, B. T., Patel, D. M., Kryvenko, O. N., Heidman, L., Kumar, A., Morgan, W. M., Ban, Y., Reis, I. M., Chen, X., Gonzalgo, M. L., Jorda, M., Burnstein, K. L. & Zhang, F., Feb 7 2019, In : Oncogene. 38, 6, p. 838-851 14 p.

Research output: Contribution to journalArticle

3 Scopus citations
2018

Alterations of tumor microenvironment by nitric oxide impedes castration-resistant prostate cancer growth

Arora, H., Panara, K., Kuchakulla, M., Kulandavelu, S., Burnstein, K. L., Schally, A. V., Hare, J. M. & Ramasamy, R., Oct 30 2018, In : Proceedings of the National Academy of Sciences of the United States of America. 115, 44, p. 11298-11303 6 p.

Research output: Contribution to journalArticle

4 Scopus citations

Identification of an oncogenic network with prognostic and therapeutic value in prostate cancer

Magani, F., Bray, E. R., Martinez, M. J., Zhao, N., Copello, V. A., Heidman, L., Peacock, S. O., Wiley, D. J., D'Urso, G. & Burnstein, K. L., Aug 2018, In : Molecular Systems Biology. 14, 8, e8202.

Research output: Contribution to journalArticle

6 Scopus citations

Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting

Luo, J., Attard, G., Balk, S. P., Bevan, C., Burnstein, K., Cato, L., Cherkasov, A., De Bono, J. S., Dong, Y., Gao, A. C., Gleave, M., Heemers, H., Kanayama, M., Kittler, R., Lang, J. M., Lee, R. J., Logothetis, C. J., Matusik, R., Plymate, S., Sawyers, C. L. & 7 others, Selth, L. A., Soule, H., Tilley, W., Weigel, N. L., Zoubeidi, A., Dehm, S. M. & Raj, G. V., May 2018, In : European urology. 73, 5, p. 715-723 9 p.

Research output: Contribution to journalArticle

41 Scopus citations
2017

Targeting AR variant–coactivator interactions to exploit prostate cancer vulnerabilities

Magani, F., Peacock, S. O., Rice, M. A., Martinez, M. J., Greene, A. M., Magani, P. S., Lyles, R., Weitz, J. R. & Burnstein, K. L., Nov 1 2017, In : Molecular Cancer Research. 15, 11, p. 1469-1480 12 p.

Research output: Contribution to journalArticle

9 Scopus citations

Thioredoxin-1 protects against androgen receptor-induced redox vulnerability in castration-resistant prostate cancer

Samaranayake, G. J., Troccoli, C. I., Huynh, M., Lyles, R. D. Z., Kage, K., Win, A., Lakshmanan, V., Kwon, D., Ban, Y., Chen, X., Zarco, E. R., Jorda, M., Burnstein, K. L. & Rai, P., Dec 1 2017, In : Nature Communications. 8, 1, 1204.

Research output: Contribution to journalArticle

12 Scopus citations
2016

Edelfosine promotes apoptosis in androgen-deprived prostate tumors by increasing atf3 and inhibiting androgen receptor activity

Udayakumar, T., Stoyanova, R., Shareef, M. M., Mu, Z., Philip, S., Burnstein, K. L. & Pollack, A., Jun 1 2016, In : Molecular Cancer Therapeutics. 15, 6, p. 1353-1363 11 p.

Research output: Contribution to journalArticle

7 Scopus citations

The microRNA-23b/-27b cluster suppresses prostate cancer metastasis via Huntingtin-interacting protein 1-related

Rice, M. A., Ishteiwy, R. A., Magani, F., Udayakumar, T., Reiner, T., Yates, T. J., Miller, P., Perez-Stable, C., Rai, P., Verdun, R., Dykxhoorn, D. M. & Burnstein, K. L., Sep 8 2016, In : Oncogene. 35, 36, p. 4752-4761 10 p.

Research output: Contribution to journalArticle

20 Scopus citations
2015

Essential components of cancer education

Welch, D. R., Antalis, T. M., Burnstein, K., Vona-Davis, L., Jensen, R. A., Nakshatri, H., Riegel, A. T., Spitz, D. R., Watson, D. K. & Weiner, G. J., Dec 15 2015, In : Cancer Research. 75, 24, p. 5202-5205 4 p.

Research output: Contribution to journalArticle

4 Scopus citations
2013
17 Scopus citations

Signaling mechanisms of Vav3, a guanine nucleotide exchange factor and androgen receptor coactivator, in physiology and prostate cancer progression

Lyons, L. S. & Burnstein, K. L., Jan 1 2013, Prostate Cancer: Biochemistry, Molecular Biology and Genetics. Springer New York, p. 187-205 19 p.

Research output: Chapter in Book/Report/Conference proceedingChapter

18 Scopus citations
2012

A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer

Rao, S., Lyons, L. S., Fahrenholtz, C. D., Wu, F., Farooq, A., Balkan, W. & Burnstein, K. L., Feb 1 2012, In : Oncogene. 31, 6, p. 716-727 12 p.

Research output: Contribution to journalArticle

34 Scopus citations

In vivo 17β-estradiol treatment contributes to podocyte actin stabilization in female db/db mice

Catanuto, P., Fornoni, A., Pereira-Simon, S., Wu, F., Burnstein, K. L., Xia, X., Conti, F., Lenzi, A. & Elliot, S., Dec 1 2012, In : Endocrinology. 153, 12, p. 5888-5895 8 p.

Research output: Contribution to journalArticle

9 Scopus citations

The microRNA -23b/-27b Cluster Suppresses the Metastatic Phenotype of Castration-Resistant Prostate Cancer Cells

Ishteiwy, R. A., Ward, T. M., Dykxhoorn, D. M. & Burnstein, K. L., Dec 29 2012, In : PloS one. 7, 12, e52106.

Research output: Contribution to journalArticle

67 Scopus citations

Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival

Peacock, S. O., Fahrenholtz, C. D. & Burnstein, K. L., Dec 1 2012, In : Molecular Endocrinology. 26, 12, p. 1967-1979 13 p.

Research output: Contribution to journalArticle

42 Scopus citations
2011

Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer

Rosenblatt, A. E., Garcia, M. I., Lyons, L., Xie, Y., Maiorino, C., Désiré, L., Slingerland, J. & Burnstein, K. L., Apr 2011, In : Endocrine-related cancer. 18, 2, p. 207-219 13 p.

Research output: Contribution to journalArticle

33 Scopus citations